Biogen Idec Ma Inc.

Biogen Ma Inc.

Biogen, Incorporated

Paula S Hochman

Jeffrey L Browning

Christopher D Benjamin

Tatiana Plavina

Adrian Whitty

Margot Brickelmaier

Michaela Lerner

Laura Runkel

Paul David Rennert

Blake Pepinsky

Fabienne MacKay

Fabienne Mackay

Methods and apparatus for assaying the level of analytes in a sample, related to VLA-4, are disclosed. A method of decreasing the level of an anti-integrin antibody in a subject is described including a) contacting a biological sample from a subject with a detectable capture agent associated with a substrate, wherein the capture agent can bind an anti-integrin antibody in the sample; b) detecting binding of the capture agent with the level of the anti-integrin antibody; and c) treating the subject with plasma exchange until the level of the anti-integrin antibody in the sample reaches a predetermined level.

Anti-VLA-4 related assays

An interferon beta polypeptide comprising interferon-beta 1a coupled to a polymer containing a polyalkylene glycol moiety wherein the interferon-beta-1a and the polyalkylene glycol moiety are arranged such that the interferon-beta-1a has an enhanced activity relative to another therapeutic form of interferon beta (interferon-beta-1b) and exhibits no decrease in activity as compared to non-conjugated interferon-beta-1a. The conjugates of the invention are usefully employed in therapeutic as well as non-therapeutic, e.g., diagnostic, applications.

Polymer conjugates of interferon beta-1A and uses

This invention relates to compositions and methods comprising 'lymphotoxin-&#x3b2;-receptor blocking agents', which block lymphotoxin-&#x3b2; receptor signalling. Lymphotoxin-&#x3b2; receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-&#x3b2; receptor extracellular domain that act as lymphotoxin-&#x3b2; receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-&#x3b2; receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-&#x3b2; receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-&#x3b2; receptor signalling is provided.

Methods for inhibiting lymphotoxin-&#x3b2; receptor signaling in TH1 cell-associated disorders

Compositions and methods comprising 'lymphotoxin-&#x3b2; receptor blocking agents' which block lymphotoxin-&#x3b2; receptor signalling and are useful for altering immunological diseases, and particularly antibody mediated immune responses.

Soluble lymphotoxin-beta receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological diseases

This invention relates to compositions and methods comprising 'lymphotoxin-&#x3b2;-receptor blocking agents', which block lymphotoxin-&#x3b2; receptor signalling. Lymphotoxin-&#x3b2; receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-&#x3b2;.receptor extracellular domain that act as lymphotoxin-&#x3b2; receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-&#x3b2;. receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-&#x3b2; receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-&#x3b2; receptor signalling is provided.

Soluble lymphotoxin-&#x3b2; receptor fusion protein and methods for inhibiting lymphotoxin &#x3b2;-receptor signaling

Compositions and methods comprising 'lymphotoxin-&#x3b2; receptor blocking agents' which block lymphotoxin-&#x3b2; receptor signaling and are useful for altering immunological diseases, and particularly antibody mediated immune responses.

A fusion polypeptide is described having the amino acid sequence X-Y-Z, or portion thereof, comprising the amino acid sequence of a glycosylated interferon-beta (X); Y is an optional linker moiety; and Z is a polypeptide comprising at least a portion of a polypeptide other than glycosylated interferon-beta. It is preferred that X is human interferon-beta-1a. Mutants of interferon-beta-1a are also described.

Interferon-beta-1a-immunoglobulin fusion proteins and uses

This invention relates to compositions and methods comprising 'lymphotoxin-&#x3b2; receptor blocking agents', which block lymphotoxin-&#x3b2; receptor signalling. Lymphotoxin-&#x3b2; receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-&#x3b2; receptor extracellular domain that act as lymphotoxin-&#x3b2; receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-&#x3b2; receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-&#x3b2; receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-&#x3b2; receptor signalling is provided.

Growing community of inventors

Newton, MA, United States of America

Paula S Hochman